Late-Onset Retinal Degeneration

Symptoms, Doctors, Treatments, Advances & More

Peter Kaiser is an Ophthalmologist practicing medicine in Cleveland, Ohio. He has been practicing medicine for over 38 years. Dr. Kaiser is rated as an Elite provider by MediFind in the treatment of Late-Onset Retinal Degeneration. He is also highly rated in 26 other conditions, according to our data. His clinical expertise encompasses Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Diabetic Retinopathy, Vitrectomy, and Osteotomy. Dr. Kaiser is board certified in American Board Of Ophthalmology, 1998.

I’m a retina specialist who takes care of patients who have problems with the back of the eye. When a patient comes to see me, I like getting to know them and their history, so that I can tailor their treatment. My patients come from a variety of different backgrounds, so I find that I often learn as much from them as they do from me. Everybody has a different story and I very much like to learn about the patients to whom I provide care. Duke is a great place at which to work and from which to seek treatment because it’s a very collaborative institution. Everyone works together to do what’s best for the patient. Outside of work, I like to spend as much time as possible with my family. I also enjoy cooking, playing sports and watching sports. Dr. Jaffe is rated as an Elite provider by MediFind in the treatment of Late-Onset Retinal Degeneration. He is also highly rated in 22 other conditions, according to our data. His clinical expertise encompasses Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Geographic Atrophy, Vitrectomy, and Cataract Removal. Dr. Jaffe is board certified in American Board Of Ophthalmology, Ophthalmology.

Peter A. Campochiaro, M.D. is the George S. and Dolores Doré Eccles Professor of Ophthalmology and Neuroscience at the Wilmer Eye Institute, Johns Hopkins University School of Medicine. He is a clinician-scientist who directs a research laboratory and conducts clinical trials. His laboratory research is directed at understanding the pathogenesis of ocular neovascularization and excessive retinal vascular permeability, and the mechanism of cone cell death in inherited retinal degenerations. He helped to determine the importance of vascular endothelial growth factor (VEGF), hypoxia-inducible factor-1, and Tie2 in retinal and choroidal vascular diseases. The clinical trial group under Dr. Campochairo provided the first demonstration of the benefits of suppression of VEGF in diabetic macular edema and retinal vein occlusion. He has developed strategies for sustained suppression of VEGF that are currently being tested in clinical trials. Dr. Campochiaro trained at the University of Notre Dame, Johns Hopkins School of Medicine, and the University of Virginia. He did a vitreoretinal fellowship and research fellowships at Johns Hopkins and joined the faculty of the University of Virginia in 1984. He became professor of Ophthalmology and Neuroscience at the Wilmer Eye Institute, Johns Hopkins in 1991. Dr. Campochiaro is rated as an Elite provider by MediFind in the treatment of Late-Onset Retinal Degeneration. He is also highly rated in 18 other conditions, according to our data. His clinical expertise encompasses Retinal Vein Occlusion, Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), Trabeculectomy, and Vitrectomy. Dr. Campochiaro is board certified in American Board Of Ophthalmology.